These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8900933)

  • 1. Vaccination of C57BL/6 mice against cutaneous leishmaniosis. Kinetics of antibody synthesis and induction of cellular responses.
    Lezama-Dávila CM; Gallagher G
    In Vivo; 1995; 9(5):519-24. PubMed ID: 8900933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination of different strains of mice against cutaneous leishmaniosis: usefulness of membrane antigens encapsulated into liposomes by intraperitoneal and subcutaneous administration.
    Lezama-Dávila CM
    Arch Med Res; 1997; 28(1):47-53. PubMed ID: 9078587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
    Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
    Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
    Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T; Anam K; Ali N
    Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of protein malnutrition on the course of Leishmania mexicana infection in C57Bl/6 mice: nutrition and susceptibility to leishmaniasis.
    Pérez H; Malavé I; Arredondo B
    Clin Exp Immunol; 1979 Dec; 38(3):453-60. PubMed ID: 535184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
    Badiee A; Jaafari MR; Khamesipour A
    Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection.
    Uyttenhove C; Arendse B; Stroobant V; Brombacher F; Van Snick J
    Eur J Immunol; 2004 Dec; 34(12):3572-81. PubMed ID: 15549728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroconversion against Lutzomyia longipalpis saliva concurrent with the development of anti-Leishmania chagasi delayed-type hypersensitivity.
    Gomes RB; Brodskyn C; de Oliveira CI; Costa J; Miranda JC; Caldas A; Valenzuela JG; Barral-Netto M; Barral A
    J Infect Dis; 2002 Nov; 186(10):1530-4. PubMed ID: 12404176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition.
    Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Colloids Surf B Biointerfaces; 2009 Nov; 74(1):37-44. PubMed ID: 19615870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
    Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
    Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short report: requirement of b cells for delayed type hypersensitivity-like pathology after secondary infection with Leishmania major in resistant C57BL/6 mice.
    DeKrey GK; Jones JJ; Mbow ML; Brodskyn CI; Titus RG
    Am J Trop Med Hyg; 2003 Nov; 69(5):481-3. PubMed ID: 14695084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
    Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
    Bhowmick S; Ravindran R; Ali N
    Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes.
    Ali N; Afrin F
    J Parasitol; 1997 Feb; 83(1):70-5. PubMed ID: 9057699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice.
    Rosas LE; Keiser T; Barbi J; Satoskar AA; Septer A; Kaczmarek J; Lezama-Davila CM; Satoskar AR
    Int Immunol; 2005 Oct; 17(10):1347-57. PubMed ID: 16141242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.